08:29 AM EDT, 10/17/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Friday it is initiating a phase III trial to evaluate bispecific antibody ivonescimab as a first line therapy in patients with unresectable metastatic colorectal cancer.

The biopharmaceutical company said the trial represents a first global study of ivonescimab beyond non-small cell lung cancer. The phase III trial will evaluate the antibody plus chemotherapy compared with bevacizumab plus chemotherapy.

Summit said it plans to enroll approximately 600 patients in the trial and that the study's primary endpoint is progression-free survival.

Summit Therapeutics ( SMMT ) shares were down 1.7% in recent premarket activity.